HHLR ADVISORS, LTD. - Q2 2020 holdings

$10.9 Billion is the total value of HHLR ADVISORS, LTD.'s 74 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 20.0% .

 Value Shares↓ Weighting
JD SellJD.COM INCspon adr cl a$470,030,000
-2.5%
7,810,402
-34.4%
4.30%
-33.9%
BILI SellBILIBILI INCspons ads rep z$421,608,000
+76.2%
9,102,063
-10.9%
3.85%
+19.5%
ALGN SellALIGN TECHNOLOGY INC$216,908,000
+16.9%
790,365
-25.9%
1.98%
-20.7%
MDLZ SellMONDELEZ INTL INCcl a$124,305,000
-2.5%
2,431,164
-4.5%
1.14%
-33.9%
VIE SellVIELA BIO INC$121,983,000
-30.1%
2,815,868
-38.7%
1.12%
-52.6%
VIPS SellVIPSHOP HOLDINGS LIMITEDsponsored ads a$109,055,000
-0.6%
5,477,392
-22.3%
1.00%
-32.6%
BPMC SellBLUEPRINT MEDICINES CORP$106,441,000
+12.8%
1,364,631
-15.4%
0.97%
-23.5%
MYOK SellMYOKARDIA INC$66,731,000
+45.8%
690,658
-29.2%
0.61%
-1.1%
SE SellSEA LTDsponsored ads$64,182,000
+15.9%
598,489
-52.1%
0.59%
-21.3%
LN SellLINE CORPsponsored adr$33,858,000
-19.3%
676,211
-22.4%
0.31%
-45.3%
ZLAB SellZAI LAB LTDadr$32,852,000
+15.6%
400,000
-27.6%
0.30%
-21.7%
MLCO SellMELCO RESORT ENTMNT LTDadr$26,367,000
-3.3%
1,698,877
-22.7%
0.24%
-34.3%
ARVN SellARVINAS INC$20,963,000
-39.2%
625,000
-26.9%
0.19%
-58.7%
RCUS SellARCUS BIOSCIENCES INC$15,463,000
+45.2%
625,000
-18.5%
0.14%
-2.1%
NXTC SellNEXTCURE INC$13,685,000
-65.0%
638,307
-39.4%
0.12%
-76.2%
UXIN SellUXIN LTDads$4,285,000
-61.6%
2,996,543
-58.6%
0.04%
-74.0%
SFUN ExitFANG HLDGS LTDadr new$0-300,000
-100.0%
-0.01%
NVDA ExitNVIDIA CORP$0-50,000
-100.0%
-0.18%
SDC ExitSMILEDIRECTCLUB INC$0-2,898,086
-100.0%
-0.18%
SNAP ExitSNAP INCcl a$0-4,465,885
-100.0%
-0.72%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BEIGENE LTD20Q3 202326.0%
JD.COM INC20Q3 202313.1%
IQIYI INC20Q3 202312.3%
MONDELEZ INTL INC20Q3 20235.9%
KINIKSA PHARMACEUTICALS LTD20Q3 20231.6%
SOHU COM LTD20Q3 20230.6%
PINDUODUO INC19Q3 202316.1%
GOSSAMER BIO INC19Q3 20232.3%
BRIDGEBIO PHARMA INC18Q3 20233.4%
MELCO RESORTS AND ENTMT LTD18Q1 20232.8%

View HHLR ADVISORS, LTD.'s complete holdings history.

Latest significant ownerships (13-D/G)
HHLR ADVISORS, LTD. Q2 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
I-MabJune 30, 202315,891,2118.3%
BeiGene, Ltd.February 14, 2023147,043,05810.9%
Gossamer Bio, Inc.February 14, 20234,974,0415.3%
On Holding AGFebruary 14, 20235,468,5041.9%
Root, Inc.February 14, 2023138,9771.5%
Yatsen Holding LtdFebruary 14, 2023300,560,60219.1%
iQIYI, Inc.July 11, 2022149,075,9125.0%
Apellis Pharmaceuticals, Inc.February 14, 2022? ?
Beam Therapeutics Inc.February 14, 2022? ?
Futu Holdings LtdFebruary 14, 20222-

View HHLR ADVISORS, LTD.'s complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
42024-02-01
13F-HR2023-11-14

View HHLR ADVISORS, LTD.'s complete filings history.

Compare quarters

Export HHLR ADVISORS, LTD.'s holdings